Emerging treatments
Pegargiminase
Pegargiminase, an arginine deprivation therapy, has been studied in a phase 3 randomised placebo-controlled trial. Patients with non-epithelioid pleural mesothelioma were assigned to standard platinum-based chemotherapy plus pegargiminase, or to standard chemotherapy plus placebo. Pegargiminase plus chemotherapy increased overall survival with a favourable safety profile.[107]
Use of this content is subject to our disclaimer